Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Clinical Data
Pharma
ADA: Lilly's Foundayo pads case against semaglutide in diabetes
With an obesity green light already in hand, Eli Lilly is pushing for its newly launched Foundayo (orforglipron) to break into Type 2 diabetes.
Fraiser Kansteiner
Jun 8, 2026 3:42pm
In endometrial cancer, Merck and Kelun score with sac-TMT
May 18, 2026 11:21am
Novo, Lilly unveil new obesity data as GLP-1 rivalry grows
May 13, 2026 11:18am
Novo eyes adolescent diabetes approval for oral semaglutide
Apr 23, 2026 11:03am
More transparency, evidence needed for accelerated nods: ICER
Apr 17, 2026 11:22am
Lilly answers FDA's call for more Foundayo safety information
Apr 16, 2026 9:43am
